Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases

被引:28
作者
Ivey, F. Douglas [1 ]
Wang, Lili [1 ]
Demirbas, Didem [1 ]
Allain, Christina [1 ]
Hoffman, Charles S. [1 ]
机构
[1] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA
关键词
Schizosaccharomyces pombe; cAMP; phosphodiesterase; high throughput; inhibitors;
D O I
10.1177/1087057107312127
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Cyclic nucleotide phosphodiesterases (PDEs) comprise a superfamily of enzymes that serve as drug targets in many human diseases. There is a continuing need to identify high-specificity inhibitors that affect individual PDE families or even subtypes within a single family. The authors describe a fission yeast-based high-throughput screen to detect inhibitors of heterologously expressed adenosine 3', 5'-cyclic monophosphate (cAMP) PDEs. The utility of this system is demonstrated by the construction and characterization of strains that express mammalian PDE2A, PDE4A, PDE4B, and PDE8A and respond appropriately to known PDE2A and PDE4 inhibitors. High-throughput screens of 2 bioactive compound libraries for PDE inhibitors using strains expressing PDE2A, PDE4A, PDE4B, and the yeast PDE Cgs2 identified known PDE inhibitors and members of compound classes associated with PDE inhibition. The authors verified that the furanocoumarin imperatorin is a PDE4 inhibitor based on its ability to produce a PDE4-specific elevation of cAMP levels. This platform can be used to identify PDE activators, as well as genes encoding PDE regulators, which could serve as targets for future drug screens.
引用
收藏
页码:62 / 71
页数:10
相关论文
共 41 条
[1]
ROLIPRAM, A SPECIFIC TYPE-IV PHOSPHODIESTERASE INHIBITOR, IS A POTENT INHIBITOR OF HIV-1 REPLICATION [J].
ANGEL, JB ;
SAGET, BM ;
WALSH, SP ;
GRETEN, TF ;
DINARELLO, CA ;
SKOLNIK, PR ;
ENDRES, S .
AIDS, 1995, 9 (10) :1137-1144
[2]
Yeast model system for study of mammalian phosphodiesterases [J].
Atienza, JM ;
Colicelli, J .
METHODS, 1998, 14 (01) :35-42
[3]
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use [J].
Bender, Andrew T. ;
Beavo, Joseph A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :488-520
[4]
Phosphodiesterase inhibitors [J].
Boswell-Smith, V ;
Spina, D ;
Page, CP .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 :S252-S257
[5]
BOVALINI L, 1987, Z NATURFORSCH C, V42, P1009
[6]
Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse [J].
Cherry, JA ;
Thompson, BE ;
Pho, V .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2001, 1518 (1-2) :27-35
[7]
EXPRESSION OF 3 MAMMALIAN CDNAS THAT INTERFERE WITH RAS FUNCTION IN SACCHAROMYCES-CEREVISIAE [J].
COLICELLI, J ;
NICOLETTE, C ;
BIRCHMEIER, C ;
RODGERS, L ;
RIGGS, M ;
WIGLER, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2913-2917
[8]
Degols G, 1996, MOL CELL BIOL, V16, P2870
[9]
INTERACTION BETWEEN RAN1+ PROTEIN-KINASE AND CAMP DEPENDENT PROTEIN-KINASE AS NEGATIVE REGULATORS OF FISSION YEAST MEIOSIS [J].
DEVOTI, J ;
SEYDOUX, G ;
BEACH, D ;
MCLEOD, M .
EMBO JOURNAL, 1991, 10 (12) :3759-3768
[10]
Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction [J].
Duarte, J ;
Lugnier, C ;
Torres, AI ;
Perez-Vizcaino, F ;
Zarzuelo, A ;
Tamargo, U .
GENERAL PHARMACOLOGY, 1999, 32 (01) :71-74